Is cEACAM6 a novel biomarker in pancreatic adenocarcinoma and PanIN lesions?
CEACAM6 is a novel biomarker for pancreatic adenocarcinoma. CEACAM6 warrants further evaluation as both a prognostic factor and a therapeutic target in pancreatic cancer.
Alteration of p15 and p16 genes and overexpression of TGF-alpha appears to be an event in bladder cancer that occurs more frequently in schistosomal bladder cancer and SCC, and may play an important role in their development. These observations may provide insight into treatment guided by molecular changes.